Lexicon Pharmaceuticals is a U.S. biopharmaceutical company that discovers and develops small-molecule medicines, historically guided by large-scale mouse genetics research. Its commercial and late-stage focus has included therapies in metabolism and cardiometabolic disease—such as an SGLT inhibitor franchise—and other specialty indications. The business model centers on R&D-driven assets, partnerships and commercialization of niche prescription drugs rather than a broad primary-care portfolio.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1.3 | — | -25.3 | — |
| Q2 2025 | 28.9 | — | 3.3 | — |
| Q3 2025 | 14.2 | — | -12.8 | — |
| Q4 2025 | 5.5 | — | -15.5 | — |
| Q1 2026 | 21.1 | 1,572.1% | -1 | — |
| Q2 2026 | 0.7 | -97.6% | -31.8 | -1,077.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Candel Therapeutics, Inc. (CADL), Immix Biopharma, Inc. (IMMX), Horizon Bancorp, Inc. (HBNC), QuidelOrtho Corporation (QDEL), American Bitcoin Corp (ABTC), NANO Nuclear Energy Inc. (NNE)